Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Harnessing the Power of Two: High-Dose Stem Cell Haploidentical Transplant in Hematologic Malignancies - A Prospective Trial.

Transplantation and cellular therapy·2026

Same author

Bidirectional regulatory effects of frequency-dependent splenic apex electrical stimulation on peripheral immune suppression and central neural repair after spinal cord injury.

Neural regeneration research·2026

Same author

Absent Cyclin D1 Expression in Myeloid Sarcomas Distinguishes From Malignant Histiocytic Neoplasms: When Morphologic Ambiguity is Deceptive.

The American journal of surgical pathology·2026

Same authorSame journal

The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.

Hematology/oncology and stem cell therapy·2026

Same author

Synergistic Neuroprotection of Fe<sub>3</sub>O<sub>4</sub> Nanoparticles Combined with Intermittent Theta Burst Stimulation in Ischemic Stroke via Nrf2-Mediated Ferroptosis Regulation.

International journal of nanomedicine·2026

Same author

Targeting the microbiota-gut-brain axis in post-stroke insomnia: a phase-dependent therapeutic framework.

Frontiers in neuroscience·2026

Search research articles

Related Experiment Video

Updated: Aug 16, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric Antigen Receptor T Cell Therapy For Solid Tumors.

Jingmei Hsu¹, Yang Yang², Mia Gergis³

¹Weill Cornell Medicine, United States.

Hematology/Oncology and Stem Cell Therapy

|December 20, 2022

Summary

Chimeric antigen receptor T (CAR T) cell therapy shows promise for solid tumors but faces challenges. This review covers early successes, limitations, and innovative strategies to advance CAR T therapy in solid tumors.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Aug 16, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

Chimeric antigen receptor T (CAR T) cell therapy has transformed lymphoid cancer treatment.
Significant hurdles remain for CAR T therapy's application in solid tumors.

Purpose of the Study:

To review early clinical investigations of CAR T therapy in solid tumors.
To highlight key successes, challenges, and innovative strategies for improving efficacy.

Main Methods:

Literature review of early-phase clinical trials.
Analysis of reported outcomes, toxicities, and therapeutic approaches.

Main Results:

CAR T therapy has demonstrated preliminary efficacy in certain solid tumors.
Challenges include target antigen heterogeneity, the tumor microenvironment, and T cell persistence.
Strategies involve novel target selection, combination therapies, and engineering approaches.

Conclusions:

Advancing CAR T therapy for solid tumors requires overcoming significant obstacles.
Continued innovation in target identification and therapeutic design is crucial for clinical success.